Efficacy and safety of SHEN26, a novel oral small molecular RdRp inhibitor for COVID-19 treatment: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial - Bai, Jiangtao; Asakawa, Tetsuya; Yuan, Wenfang; Lin, Yuanlong; Ju, Hao; Xu, Dandan; Yang, Mingming; Li, Shuo; Li, Guanguan; Guo, Deyin; Lu, Hongzhou; Zhang, Xumu (Virology journal, 2025)
Keywords: Administration, Oral; Adult; adults; Aged; Antiviral agents; Antiviral Agents - administration & dosage; Antiviral Agents - adverse effects; Antiviral Agents - pharmacokinetics; Antiviral Agents - therapeutic use; clinical trials; COVID-19; COVID-19 - virology; COVID-19 Drug Treatment; COVID-19 infection; death; Double-Blind Method; Efficacy and safety; Enzyme inhibitors; Female; Humans; Male; Middle Aged; Oral small molecular antiviral drug; pharmacokinetics; placebos; RdRp inhibitor; renal function; RNA; RNA, Viral; RNA-Dependent RNA Polymerase - antagonists & inhibitors; RNA-directed RNA polymerase; SARS-CoV-2 - drug effects; Testing; Treatment Outcome; Viral load; Viral Load - drug effects; viruses; China; COVID-19; RdRp inhibitor; Oral small molecular antiviral drug; Efficacy and safety; Viral load